

Cetiprin advertisement.


[s.l.]: [s.n.], 1972

https://digital.library.wisc.edu/1711.dl/N7MHP4QZKCLFJ85

http://rightsstatements.org/vocab/InC/1.0/

The libraries provide public access to a wide range of material, including online exhibits, digitized collections, archival finding aids, our catalog, online articles, and a growing range of materials in many media.

When possible, we provide rights information in catalog records, finding aids, and other metadata that accompanies collections or items. However, it is always the user's obligation to evaluate copyright and rights issues in light of their own use.



Prescribing Information Presentation Cetiprin Tablets 100mg: White, coated and slightly bulged tablets of 10 mm diameter, marked (CT) on the side. Each tablet contains 100 mg emepronium bromide Uses Main pharmacological action. Emepronium bromide is a quaternary ammonium anticholinergic drug which blocks peripheral cholinergic nerves and ganglionic transmission. In man, it increases bladder cagacity, delays the first desire to void and decreases voiding pressure. Indications 1 Uninary frequency and incontinence in old people. 2 Nocturnal frequency. 3 After bladder surgery, prostatectomy or bladder radiotherapy. In order to obtain an optimal response the treatment should continue for at least three to four weeks. Dosage and administration Route of administration. By mouth with an adequate amount of fluid (minimum 100 ml). Cetiprin tablets should always be taken with the patient sitting or standing and the patient should not lie down within 10-15 minutes following ingestion. Recommended dosage: 1 Urinary frequency and incontinence in old people up to 200 mg, (2 x 100 mg tablets) three times daily dependant on response. 2 Nocturnal frequency; 20-40 mg at bedtime. 3

After bladder surgery, prostatectomy or bladder radiotherapy 200 mg, (2 x 100 mg tablets) three times daily in most cases. Contra-indications, warnings, etc. Cetiprin is contra-indicated in the following 1 in patients with symptoms or signs of oesophageal obstruction. 2 in patients with pre-existing oesophagits. 3 in patients with prostatic enlargement associated with large amounts of residual urine and flaccid bladder. Precautions 1 Caution should be observed in patients with glaucoma or gastric retention. 2 No teratogenic effect has been observed but the usual precautions in early pregnancy should be observed. Side-effects: Rarely, dryness of the mouth. Ulceration of the gums and mouth has been reported, particularly in geriatric patients who hold the tablets in their mouths for long periods. There have also been instances of oesophageal ulceration when the tablets have not been swallowed with an adequate amount of fluid. See dosage recommendations above. Package quantities Cetiprin 100 mg. Bottles of 50, 250 and 500 tablets. UK Product licence number 0022/5001 Eire Product authorisation number 187/7/1 Basic NHS price 32p daily.





KabiVitrum Limited, KabiVitrum House, Riverside Way, Uxbridge, Middlesex UB8 2YF Tel: Üxbridge (0895) 51144 KabiVitrum, Cahill May Roberts Limited, P.O. Box 1090, Chapelizod, Dublin 20. Tel: 01 26 71 11